CJC-1295 (No DAC) is a growth hormone-releasing hormone (GH-RH) that is synthetically made. It incorporates the initial 29 amino acids of the natural GHRH, referred to as GRF 1 -29, and involves certain modifications that render it more resistant and reduce its disintegration in the body. CJC -1295 (No DAC) induces the normal pituitary gland to secrete growth hormone in a natural, pulsatile pattern as does the body. CJC-1295 (No DAC) does not provide us with growth hormone itlsef, but it enhances the body’s production of growth hormone.
This maintains a normal value of hormonal feedback and reduces the chances of hormonal overload as a research risk. Research of CJC -1295 (No DAC) and other GHRH analogs has demonstrated increased growth hormone activity and enhancement of IGF-1. Under typical conditions (e.g., 100 mcg administered multiple times a day), IGF-1 increased steadily, indicating successful stimulation in the growth-hormone axis.
CJC-1295 (No DAC) has a lower half-life than DAC-containing ones. Scholars thus advise increased doses more regularly to maintain growth-hormone signals consistently.
Disclaimer: The content shared in this article is for informational purposes only; don’t take it as medical advice.
Research-Based Data About CJC-1295 (No DAC) You Should Know
CJC -1295 (No DAC), or Modified GRF 1-29, contains four amino acid substitutions at positions 2, 8, 15, and 27. Such replacements increase the resistance of the peptide to rapid enzyme degradation compared to natural GHRH or sermorelin.
These alterations give CJC1295 (No DAC) a plasma half-life of approximately 30 minutes. This is more than unmodified growth-hormone release analogs but not so long as to inhibit natural, pulsatile growth-hormone release.
It has been observed that the biological action in the secretion of growth hormone could persist 2-3 hours after subcutaneous injection, even with a short half-life. A pulse with predominant growth hormone is generally observed at that period. CJC -1295 (No DAC) in combination with larger growth-hormone pulses and increased IGF-1 levels after weeks or months in protocols involving multiple daily doses of typically 100 to 300mcg.
Indicative of this, the same GHRH analogs with regular dosage showed mean IGF-1 increases of approximately 150-160ng/ml at baseline to approximately 230-240ng/ml (or higher) after many months of daily dosage. The high levels of IGF -1 persist for days or weeks after withdrawal in a few studies, pointing towards a sustained growth-hormone axis stimulatory effect of the treatment.
CJC-1295 (No DAC) Dosage Per Day (2026 Research Overview)
CJC 1295 (No DAC) is primarily administered as subcutaneous injections multiple times daily in the research circles. This plan overcomes its short half-life and stimulates robust and natural pulses of growth hormone. Other dose 100-200 Mcg. A majority of the protocols consist of two to four injections per day, and a total of approximately 200600mcg/day. Certain settings go as high as 800mcg divided into multiple doses. The injection times are typically set to natural growth-hormone rhythms. The most common ones are on waking up, after exercise, and just before sleep.
CJC -1295 (No DAC) is frequently used in combination with a growth-hormone-releasing peptide such as ipamorelin. The two drugs are typically used at similar doses when they are administered simultaneously, typically 100300 events per injection, to enhance growth-hormone response. The protocols are usually five to seven days a week. There are those with rest days or planned cycles, e.g., 8-16 weeks of use and a break to maintain consistency.
Doses are frequently based on body weight, objectives of the study, age, and IGF-1 response. On the one hand, a general rule in conversations is 1-2mcg/kg/injection. There is a community report and data that indicate that the growth-hormone pulses can be increased and the IGF-1 level raised steadily over weeks and months with several daily, regular doses.
These guidelines are said to be well tolerated. The most frequent side effects are mild, but they manifest as temporary redness or flushing in the area of injections. It should be noted that these protocols are not standardized. They are diverse in terms of discussions on research and should be used only in research.
Where to Inject CJC-1295 (No DAC) (Injection-Site Guidance)
Investigators tend to recommend a change of site of injection so as to reduce the risk of local irritability and tissue alteration at a later stage. Typically, it is placed subcutaneously in the abdomen (not within a 2-inch or 5-cm radius of the belly button), in the front of the thigh, or in the upper arm. Others propose the upper back or hips as the alternatives. Repeated subcutaneous injections are characterized in the studies with the use of GHRH analogs, and these standard sites are supported.
This data applies to research and educational purposes. It is not medical advice and should not inform treatment. Before beginning any form of medical treatment, one should always seek the advice of a qualified medical professional.
Potential Research-Based Benefits of CJC-1295 (No DAC) in a Research Environment
CJC-1295 (No DAC) in research settings is primarily applied to induce the natural release of growth hormone of the pituitary gland in a pulsatile manner. In the long term, it enhances the activity of growth hormone and elevates levels of IGF-1 that researchers associate with several physiological outcomes.
Review of literature and community guidelines has documented the following effects:
1. Increased Growth Hormone Secretion
Stronger and more frequent growth hormone pulses are generated by taking several doses per day. Such pulses simulate the natural pattern in the body and increase the overall growth hormone secretion as opposed to the baseline levels.
2. Sustained Elevation of IGF-1 Levels
Regular use in research studies has been linked to progressive increments in circulating IGF-1. In numerous experiments, the increase of IGF 1 above the baseline is about 50 to 100 percent in a few weeks to months, which is evidence of the growth hormone axis being stimulated.
3. Improved Body Composition
There are indications of a potential increase in lean muscle-mass and a decrease in body fat, particularly visceral fat. These modifications are associated with anabolic and fat-dissolution effects of high levels of growth hormone and IGF-1.
4. Enhanced Recovery and Repair
Subjects in research environments often report improved recovery following physical stress or intense training. This is commonly attributed to increased protein synthesis and more efficient tissue repair processes.
5. Better Sleep Quality
Sooner administration is in accordance with the natural release of growth hormone during deep sleep. There are often deep, more restorative patterns of sleep that are recorded in protocols under such circumstances.
6. Skin, Hair, and Connective Tissue Changes
Increased IGF -1 activity relates to increased collagen production. Some of the results are better skin elasticity, skin thickness, and more robust nails and hair.
7. Potential Bone Density Support
Modest increases in the bone mineral density have been attributed to long-term growth hormone and IGF1 axis stimulation.
8. Overall Metabolic and Longevity Related Effects
The role of CJC‑1295 in promoting metabolic well-being, energy, and overall energy is being investigated by researchers by keeping an intensive growth hormone secretion without disrupting the natural hormonal responses.
These have dose-dependent effects that are most evident when administered on a regular, daily basis throughout several weeks or months. Commonly, responses to individual differences differ depending on the age, the initial growth hormone levels, the diet, the exercise levels, and the protocol design.
None of the information presented should be taken to be medical advice and is only meant to be used as a research and educational tool. CJC‑1295 (No DAC) is a research-only drug.
Risks and Safety Concerns
When CJC-1295 (No DAC) is applied in the context of community protocols, it has good toleration, generally in a research setting. Nevertheless, just like any substance that influences the activity of growth hormone, certain side effects and safety concerns are an issue of concern that must be evaluated thoroughly.
Commonly reported side effects in research observations include:
- Local reactions to injection include redness, itching, swelling, or slight discomfort.
- Flushing or short-term warmth immediately after the injection.
- Mild headache or dizziness.
- Finite fatigue or lethargy.
Less common or dose-dependent effects reported in some research settings include:
- Edema or retention of water, or slight.
- Angina or pains like carpal tunnel syndrome.
- numbness or tingling in hands or feet.
- Small, typically transient insulin resistance alterations.
Longer-term or theoretical concerns related to sustained elevation of growth hormone and IGF-1 levels include:
- Potential pituitary desensitization in high dosage, despite being less frequent with pulsatile regimens.
- Theoretical risk of triggering the development of existing tumors or abnormal cells, because growth hormone and IGF-1 can affect cell multiplication.
- The possibility of ruining natural growth hormone feedback in case of improper cycling of the protocols.
The majority of the side effects reported are mild and have a temporary nature. Research settings tend to mitigate risks by initially using low doses, modifying protocols progressively, measuring IGF -1 levels, and scheduling off periods. CJC 1295 (No DAC) has not been approved by the FDA as a therapeutic agent in human beings and is a research-only compound. Outside a controlled research environment is not recommended to be used. In any peptide study, safety must be the main priority.
Realistic Timeline and Expected Results from CJC-1295 (No DAC) in a Research Environment
CJC -1295 (No DAC) is more likely to exhibit cumulative effects in research settings where multiple daily administrations are used regularly. These developments are achieved due to continuous stimulation of natural growth hormone pulses and a gradual increase in the levels of IGF-1. The responses are diverse in relation to age, initial levels of growth hormone, nutrition, exercise, sleep quality, as well as use of the peptide alone or in conjunction with a growth hormone-releasing peptide like Ipamorelin.
Weeks 1 to 2
Early alterations can consist of more profound and restorative rest, better recovery following physical exercise, and a mild rise in daily excitement or general vitality. Subtle changes in mood or skin hydration also occur in this phase, according to some reports.
Weeks 3 to 4
Effects are more pronounced as the exposure persists. The results of the observations are usually better training results, less pain in the joints, and initial fat loss, particularly on the abdomen. Inter-session recovery is also maintained to be improved, and sleep quality remains elevated.
Months 1 to 3
The more visible changes are usually reported during this period. These can include a decrease in body fat, lean body mass, and muscle strength. The skin can become more elastic and thick, and hair and nails usually become stronger. The levels of IGF-1 generally increase at a considerable level, which may be by 50-100 percent above the baseline with the regular dosage.
Months 3 to 6
The research results show more prominent changes in months 3 to 6, including the body building up muscle definition, reducing fat, and increasing connective tissue, and slight changes in bone density indicators in longer studies. The appearance of the skin is enhanced, and other anti-aging markers are more visible after continued use.
Beyond 6 Months
The studies made longer stress the significance of cycling. The typical schemes are eight to twelve weeks on with a scheduled break. This contributes to being responsive. Benefits can reduce with time without breaks.
These are rough schedules and are estimated by observations in the research and community reports. Individual responses vary. The good outcome is generally expected when the treatment is supplemented with good nutrition, resistance exercise, and healthy lifestyle practices.
All the data provided is highly confidential and is only used in research and educational purposes in controlled environments. CJC -1295 (No 0 DAC ) is not intended to be used in human therapy but is used in research.
CJC-1295 (No DAC) Research Timeline (Table)
The table below provides a high-level summary of typical research observations using multiple daily dosing protocols (100–200 mcg per injection, 2–4 times daily). For detailed explanations of effects, see the “Realistic Timeline and Expected Results” section above.
| Time Frame | Key Observations | Notes |
| Weeks 1-2 | Early sleep benefits, small energy, and recovery benefits | The effect is mostly subjective; IGF-1 initiates growth. |
| Weeks 3-4 | Early performance increase, first weight loss | You should take the dose regularly. |
| Months 1-3 | Lean muscle, increased strength, and observed IGF -1 increase. | Most visible body composition changes occur here |
| Months 3-6 | Peak of muscles, fat burning, and connective tissue gains | Most visible body composition changes occur here |
| Beyond 6 Months | Maintained benefits with cycling; possible plateau without breaks | Cycling is recommended to preserve responsiveness |
Disclaimer: The table is purely for research and educational purposes. The outcomes are unpredictable and vary significantly. CJC-1295 (No DAC) is manufactured exclusively as a research-grade preparation not to be used as a therapeutic agent in human beings.
Conclusion
CJC1295 (No DAC) is most often researched as it will stimulate the natural secretion of growth hormone of the body in a pulsatile manner. Research indicates a requirement for gradual increases in the activity of growth hormone and the level of IGF-1 with time and regular dosage. The drug has a short half-life; therefore, researchers tend to provide multiple doses daily. The response can vary, and it is generally recommended to cycle the drug to make the body responsive. The CJC-1295 (No DAC) is purely research-oriented and is not approved as a therapeutic drug in human beings.